Danish biotechnology company Evaxion has unveiled promising preclinical data for its novel vaccine candidate designed to combat acute myeloid leukaemia (AML). The findings, presented recently, suggest a potential new approach in the fight against this aggressive form of blood cancer, which currently carries a significant mortality rate.
AML is a cancer of the myeloid line of blood cells, characterised by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. According to Cancer Research UK, around 3,100 people are diagnosed with AML in the UK each year. While treatments like chemotherapy and stem cell transplants exist, outcomes can vary widely, particularly for older patients or those with high-risk disease.
The preclinical data indicates that Evaxion's vaccine candidate may be capable of stimulating an immune response specifically targeting AML cells. This approach, known as immunotherapy, harnesses the body's own defence mechanisms to identify and destroy cancer cells, potentially offering a more targeted treatment with fewer side effects than traditional chemotherapy.
Developing new therapies for AML is crucial given the challenges associated with current treatments. The disease often requires intensive chemotherapy, which can be difficult for patients to tolerate, and relapse rates remain a concern. A vaccine that could prevent relapse or even offer a first-line treatment for certain patient groups would represent a significant medical advancement.
It is important to note that these are preclinical findings, meaning the research has been conducted in laboratory settings or animal models. The next critical step would involve moving into human clinical trials to assess the vaccine's safety, dosage, and efficacy in patients. This process typically involves multiple phases and can take several years.
The NHS currently provides a range of treatments for AML, guided by NICE (National Institute for Health and Care Excellence) recommendations. Any new treatment would undergo rigorous evaluation by regulatory bodies, such as the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, before becoming available to patients.
Source: Evaxion